title: Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells.
abstract: More than 80% of patients with extremity sarcoma ultimately develop metastases to pulmonary sites. Doxorubicin alone or in combination with other chemotherapeutic agents may result in partial or complete tumor response for sarcoma pulmonary metastases. Regardless of the response, there has been no proven survival benefit from cytotoxic chemotherapy in the treatment of localized or metastatic soft tissue sarcoma. Insulin-like growth factor-I receptor (IGF-I-R) activation may contribute to resistance to chemotherapy in mesenchymal neoplasia. IGF-I-R activation by its ligand decreases in vitro cytotoxic response of sarcoma to doxorubicin, the most active agent against soft tissue sarcoma in adults. Furthermore, IGF-I-R is frequently overexpressed in soft tissue sarcoma and may predict poor response to traditional chemotherapy. The effect of doxorubicin on a human soft tissue sarcoma cell derived from a dedifferentiated lung metastasis was evaluated using titrated doxorubicin doses with and without exogenous IGF-I (100 ng/ml). Western blot analysis was performed to evaluate levels of phosphorylated IGF-I-R under control and experimental conditions. In vitro proliferation assays were performed. Nuclear activation through IGF-I receptor mediated pathways prior to exposing sarcoma cells to doxorubicin altered the pattern of response to doxorubicin with enhanced mitogenesis (>2-fold) and blunted doxorubicin cytotoxicity (>10% change in IC50). These data suggest that activation of IGF-I receptor in sarcoma cells is a potential mechanism for tumor resistance to doxorubicin. Inhibition of IGF-I receptor activation represents a novel approach to enhance the degree and duration of response to traditional chemotherapy against soft tissue sarcoma.
authors.affiliation: Department of Surgery/Surgical Oncology, University of Tennessee Health Science Center, College of Medicine, Memphis 38163, USA. dbeech@utmem.edu
authors.forename: Derrick J
authors.initials: DJ
authors.lastname: Beech
authors.forename: Elise
authors.initials: E
authors.lastname: Perer
authors.forename: Jody
authors.initials: J
authors.lastname: Helms
authors.forename: Allison
authors.initials: A
authors.lastname: Gratzer
authors.forename: Nan
authors.initials: N
authors.lastname: Deng
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000633:toxicity*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D066298:In Vitro Techniques; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D010766:Phosphorylation; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D012509:Sarcoma / Q000378:metabolism* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000378:metabolism* / Q000473:pathology; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D014443:Tyrosine; D007334:Insulin-Like Growth Factor I; D004317:Doxorubicin; D017526:Receptor, IGF Type 1